XML 45 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Accounting Policies - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2014
Mar. 31, 2014
Sep. 30, 2014
Sep. 30, 2013
Customer
Sep. 30, 2014
Letter of Credit
Sep. 30, 2014
Outside the United States
Sep. 30, 2013
Net product revenue
Customer
Sep. 30, 2013
Net product revenue
Customer
Sep. 30, 2014
Net product revenue
Biologics, Inc.
Sep. 30, 2014
Net product revenue
Biologics, Inc.
Sep. 30, 2013
Net product revenue
Customer One Product Sales
Sep. 30, 2013
Net product revenue
Customer One Product Sales
Sep. 30, 2013
Net product revenue
Customer Two Product Sales
Sep. 30, 2013
Net product revenue
Customer Two Product Sales
Sep. 30, 2013
Net product revenue
Customer Three Product Sales
Sep. 30, 2013
Net product revenue
Customer Three Product Sales
Sep. 30, 2014
Net product revenue
Outside the United States
Sep. 30, 2013
Net product revenue
Outside the United States
Sep. 30, 2014
Net product revenue
Outside the United States
Sep. 30, 2013
Net product revenue
Outside the United States
Sep. 30, 2014
Net product revenue
Outside the United States
Germany
Sep. 30, 2013
Net product revenue
Outside the United States
Germany
Sep. 30, 2014
Net product revenue
Outside the United States
Germany
Sep. 30, 2013
Net product revenue
Outside the United States
Germany
Sep. 30, 2014
Accounts receivable
Biologics, Inc.
Sep. 30, 2013
Accounts receivable
Customer One Product Sales
Sep. 30, 2013
Accounts receivable
Customer Two Product Sales
Sep. 30, 2013
Accounts receivable
Customer Three Product Sales
Sep. 30, 2013
Accounts receivable
Customer Four Product Sales
Schedule Of Significant Accounting Policies [Line Items]                                                          
Restricted cash $ 11.3   $ 11.3   $ 9.2                                                
Aggregate gross selling price of shipments 1.7   17.3                                                    
Payment received on shipment 16.0   16.0                                                    
Customers concentration risk, percentage                 72.00% 67.00% 24.00% 24.00% 14.00% 15.00% 14.00% 14.00% 28.00% 6.00% 33.00% 3.00% 17.00% 5.00% 22.00% 2.00% 75.00% 21.00% 17.00% 14.00% 10.00%
Number of customers accounted for net product sales             3 3                                          
Number Of customers accounted for accounts receivable       4                                                  
Long lived assets           1.4                                              
Milestone payments for clinical trials   $ 3.8